TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02577068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam
Description: Patients undergoing thyroidectomy receive medications depending on the group allocation 30minutes prior to the surgery end; Nefopam 20mg, Propacetamol 2g, and Nefopam 20mg+Propacetamol 2g. In addition, patients will take the same medication every six hours during POD 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nefopam
Description: Patients undergoing thyroidectomy receive medications depending on the group allocation 30minutes prior to the surgery end; Nefopam 20mg, Propacetamol 2g, and Nefopam 20mg+Propacetamol 2g. In addition, patients will take the same medication every six hours during POD 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propacetamol
Description: Patients undergoing thyroidectomy receive medications depending on the group allocation 30minutes prior to the surgery end; Nefopam 20mg, Propacetamol 2g, and Nefopam 20mg+Propacetamol 2g. In addition, patients will take the same medication every six hours during POD 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propacetamol
Description: Patients undergoing thyroidectomy receive medications depending on the group allocation 30minutes prior to the surgery end; Nefopam 20mg, Propacetamol 2g, and Nefopam 20mg+Propacetamol 2g. In addition, patients will take the same medication every six hours during POD 1.
Study: NCT03562949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Product
Description: Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
Study: NCT02819648

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Milk Tablet
Study: NCT02064439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 59-7939
Description: 10 mg tablet once daily for 12 months
Study: NCT03562949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Product
Description: QVAR® 40 mcg (Beclomethasone Dipropionate HFA)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Product
Study: NCT01245842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand exercise program
Description: Hand exercise program three times/week for 12 weeks. In total four group sessions, otherwise home based. Weekly telephone calls from experienced physiotherapist/occupational therapist addressing adjustments of the exercise program and encouragement of program adherence.
Study: NCT02824640

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Navigation
Description: The study will follow a PN model (Check Hep C) developed by NYCDOH in collaboration with Montefiore and the community. HCV PNs will provide the following interventions to those randomized to the PN arm: coordination of HCV treatment; health promotion; assisting patients to overcome barriers; and psychosocial support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: modified Directly Observed Therapy
Description: Subjects will be observed taking medications, a minimum of 5 times a week for those enrolled in the OAT setting, and a minimum of 3 times a week for those enrolled in the community health clinic setting.
Study: NCT00333177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation training (CT)
Description: Cognitive remediation training includes computerized cognitive training plus learning skills group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy behavior training (HBT)
Description: Healthy behavior training includes group skills training in nutrition, exercise, and relaxation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy behavior training (HBT)
Description: Healthy behavior training includes group skills training in nutrition, exercise, and relaxation.
Study: NCT03555994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: MEDI0382 administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: MEDI0382 administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Liraglutide administered subcutaneously
Study: NCT06063551

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Testicular Biopsy
Description: Testicular biopsy for clinical storage and laboratory research.
Study: NCT03774121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoneurolysis
Description: A cryoprobe will be inserted percutaneously and freeze the target nerves (infrapatellar branch of the saphenous nerve \& anterior femoral cutaneous nerve) guided by ultrasound visualization.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise (GLA:D)
Description: The GLA:D program, is a standard education and exercise program for patients with osteoarthritis in Denmark. The program is performed in groups and with the supervision of an experienced physiotherapist specialized in training of musculoskeletal disorders.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Neuromuscular exercise (GLA:D)
Description: The GLA:D program, is a standard education and exercise program for patients with osteoarthritis in Denmark. The program is performed in groups and with the supervision of an experienced physiotherapist specialized in training of musculoskeletal disorders.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The sham intervention includes a similar procedure but without freezing temperatures.
Study: NCT03559556

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT angiography
Description: CT angiography uses a CT scanner to produce detailed images of both blood vessels and tissues in various parts of the body. An iodine-rich contrast material (dye) is usually injected through a small catheter placed in a vein of the arm.
Study: NCT03141970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone for 12 weeks as follows 30 mg/m2 on alternate days for 4 weeks 20 mg/m2 on alternate days for 4 weeks 10 mg/m2 on alternate days for 4 weeks
Study: NCT00153933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given intravenously on days 1, 2, 8, 11 of each 21-day cycle. Participants can remain on study treatment as long as their disease doesn't worsen and they don't experience any serious side effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-5013
Description: Orally on days 1-14 of each 21-day cycle. Participants can remain on study treatment as long as their disease doesn't worsen and they don't experience any serious side effects.
Study: NCT02113878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is a chemotherapy drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is a chemotherapy drug

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Description: IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells
Study: NCT02064439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 59-7939
Description: 20 mg tablet once daily for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA
Description: 100 mg tablet once daily for 12 months
Study: NCT02433288

Intervention type: OTHER
Group type: OTHER
Intervention: Smart phone based patient support tool
Description: The smart phone application used on the patients' smart phones will contain both the patient support tool and the questions for the clinical evaluation in the form of the Rosuvastatin Adherence questionnaire (RAQ), Beliefs about Medicine Questionnaire - General (BMQ-G), (Horne, 1999) and a Lifestyle questionnaire (LSQ) on disease understanding, lifestyle and treatment awareness. Patients in the Active group will also receive feedback on their daily rosuvastatin treatment as entered in the patient support tool.

Intervention type: OTHER
Group type: OTHER
Intervention: Control application: only for data collection
Description: the patients will have no access to the smart phone-based patient support tool. However, a smart phone application will be used to prompt patients with the questions for the clinical evaluation (RAQ, BMQ-G and LSQ).
Study: NCT02526927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HR-pQCT
Description: The Xtrem CT scanco device is a HR-pQCT used for 3D bone measurements at the tibia and the radius levels in human

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HR-pQCT
Description: The Xtrem CT scanco device is a HR-pQCT used for 3D bone measurements at the tibia and the radius levels in human

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEXA
Description: The Lunar DEXA (Dual Energy X-ray Absorptiometry) is a third generation multi-captor DEXA device that allows short duration measurements (\< 15 min). It measures Bone Mineral Density at the spine (L1-L4) and the femoral neck

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEXA
Description: The Lunar DEXA (Dual Energy X-ray Absorptiometry) is a third generation multi-captor DEXA device that allows short duration measurements (\< 15 min). It measures Bone Mineral Density at the spine (L1-L4) and the femoral neck

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples
Study: NCT04181567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroconvulsive therapy
Description: electroconvulsive therapy 2 times weekly

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electroconvulsive therapy
Description: electroconvulsive therapy 2 times weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: agomelatine
Description: agomelatine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT02549690

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone gel
Description: Apply 10mg testosterone gel to the abdomen and rub on with one finger, once a day, in the morning, then allow sites to dry and cover with clothing. Continue the treatment for 6-8 weeks until next IVF treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DHEA
Description: Take DHEA 25mg tablet orally, three times per day. Continue the treatment for 6-8 weeks, until next IVF treatment.
Study: NCT02891031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhus (Somagh)
Description: 500 mg twice daily after meal for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg twice daily after meal for 6 weeks
Study: NCT00339014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide CR and Bupropion SR
Description: Zonisamide SR and Bupropion SR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide CR and Bupropion SR
Description: Zonisamide SR and Bupropion SR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide CR and Bupropion SR
Description: Zonisamide SR and Bupropion SR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide CR and Bupropion SR
Description: Zonisamide SR and Bupropion SR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide CR and Bupropion SR
Description: Zonisamide SR and Bupropion SR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide CR and Bupropion SR
Description: Zonisamide SR and Bupropion SR

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo
Study: NCT00333177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone, administered orally (Oral Ris)
Description: Oral risperidone at dosage judged optimal by treating psychiatrist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone, administered orally (Oral Ris)
Description: Oral risperidone at dosage judged optimal by treating psychiatrist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone, administered via injection (RLAI)
Description: Risperidone in injectable form every 2 weeks, starting with 25 mg and adjusted as needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone, administered via injection (RLAI)
Description: Risperidone in injectable form every 2 weeks, starting with 25 mg and adjusted as needed
Study: NCT03376048

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wound infiltration plus TAP
Description: 1. TAP block: At the beginning of the main surgical procedure the surgeon will perform a TAP with ropivacaine infiltration, bilaterally in the anterior axillary line, between the costal margin and iliac crest in the intermuscular plane between the internal oblique and transversus abdominis muscles, the anesthesiologist under ultrasound guidance, the surgeon under laparoscopic guidance (two pops technique).~2. Wound infiltration : Wound infiltration of ropivacaine will be performed by the surgeon before skin incision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound infiltration
Description: Wound infiltration of ropivacaine will be performed by the surgeon before skin incision.
Study: NCT02301130

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mogamulizumab
Description: Mogamulizumab will be administered intravenously (IV).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mogamulizumab
Description: Mogamulizumab will be administered intravenously (IV).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4736 (Durvalumab)
Description: MEDI4736 will be administered intravenously (IV).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tremelimumab
Description: Tremelimumab will be administered intravenously (IV).
Study: NCT03633617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Solution for injection administered subcutaneously
Study: NCT04372992

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Timing of stoma closure
Description: Defining the best timing of stoma closure in relation to adjuvant therapy compliance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timing of stoma closure
Description: Defining the best timing of stoma closure in relation to adjuvant therapy compliance
Study: NCT01151254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane/sevoflurane
Description: Volatile for sedation in the CVICU while intubated

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol for sedation in the CVICU
Study: NCT02004613

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine
Study: NCT01241838

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker
Description: Routine postoperative temporary pacemaker Rate change of 65-80-95-110-125 beats/second in random order at day 3-4 after operation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pacemaker
Description: Routine postoperative temporary pacemaker Rate change of 65-80-95-110-125 beats/second in random order at day 3-4 after operation
Study: NCT02004613

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline administration matching dexmedetomidine rate of infusion
Study: NCT02113878

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Description: IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells
Study: NCT01205412

Intervention type: PROCEDURE
Intervention: Endocervical samples
Description: Endocervical samples collection during routine gynaecological examinations
Study: NCT02496208

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study: NCT04582357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity program
Description: The physical activity program is a suite of several exercises which intend to improve muscular mass of targeted muscles.
Study: NCT02496208

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT03633617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Solution for injection administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Solution for injection administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo
Study: NCT04225065

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Chlorhexidine prep prior to surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Betadine
Description: Betadine prep prior to surgery
Study: NCT03252717

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Pre-treatment blood samples will be collected for downstream analyses:~* Three 6 ml EDTA samples for proteomic and genomic work package~* One 6 ml dry sample for auto-antibodies analysis in the immunology work package~* Two 4 ml EDTA samples for DNA extraction in the immunology work package~* Two 2.5 ml PAX Gene sample for RNA extraction in the immunology work package and the non-irradiated control in the genomic work package
Study: NCT03869294

Intervention type: DRUG
Intervention: GS
Description: Gemcitabine plus S-1 (GS) was used to treat advanced pancreatic cancer
Study: NCT02065986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)

Intervention type: DRUG
Group type: OTHER
Intervention: Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)
Study: NCT02971137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation plus CBI
Description: proactive tele-health intervention combining evidence-based smoking cessation counseling augmented with behavioral approaches for coping with pain

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Standard
Description: standard telephone-based smoking cessation intervention
Study: NCT02088086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BMI screening
Description: Students in grades 3-8 will have their heights and weights measured annually at school and their BMIs calculated.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BMI screening
Description: Students in grades 3-8 will have their heights and weights measured annually at school and their BMIs calculated.
Study: NCT02680223

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Precision tinted lenses
Description: Tinted lens for patient with reading difficulty or visual stress

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Non-beneficial tinted lenses
Description: Tinted lenses that are unlikely to help reading difficulty or visual stress
Study: NCT01335568

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatocyte Matrix Implant
Description: Open surgical procedure with biopsy of liver tissue and pancreatic tissue for proceeding in institutional GMP laboratory. Implantation of autologous hepatocytes and islet cells on scaffolds into the small bowel mesentery. Usually 10 to 20 implants are used.
Study: NCT02801097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study: NCT01252797

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiosurgery (15 Gy)
Description: Group A will start at dose level II: 15 Gy~Group B will start at dose level I: 12 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (12 Gy)
Description: Group B will start at Dose Level I: 12 Gy
Study: NCT03463694

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Na Cl solution
Description: \~2.6% NaCl solution prepared from sea salt
Study: NCT02234583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5565
Description: DS-5565 15 mg tablet for oral administration
Study: NCT01150994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Assessment and Follow-up Telephone Intervention (SAFTI).
Description: Mental health evaluation in ED, followed by Post-ED counseling
Study: NCT03633617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo
Study: NCT01543971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TXA127
Description: TXA127 : 300mcg/kg per day for 5 days, injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TXA127
Description: TXA127 : 300mcg/kg per day for 5 days, injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neupogen (filgrastim)
Description: Neupogen : 10mcg/kg per day for 5 days, injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neupogen (filgrastim)
Description: Neupogen : 10mcg/kg per day for 5 days, injection